HKEX Stock Code: 01093English|繁體|简体
Financial Summary
  For the year ended 31 December
  2018
RMB'000
(Restated)
(note)
2019
RMB'000
 
(note)
2020
RMB'000
 
(note)
2021
RMB'000
 
(note)
2022
RMB'000
 
(note)
Results          
Revenue 17,716,540 22,103,192 24,942,204 27,866,870 30,936,904
Cost of sales (5,979,187) (6,192,211) (6,256,882) (6,731,776) (8,680,490)
           
Gross profit 11,737,353 15,910,981 18,685,322 21,135,094 22,256,414
Other income 139,742 243,783 264,736 411,223 603,799
Other gains or losses 155,195 48,450 376,816 242,675 291,383
Selling and distribution expenses (6,184,505) (8,712,083) (9,377,620) (10,443,422) (10,337,423)
Administrative expenses (656,597) (748,509) (945,713) (1,009,824) (1,172,842)
Research and development expenses (1,342,101) (2,000,426) (2,889,837) (3,432,590) (3,986,516)
Other expenses (26,125) (142,015) (57,036) (108,204) (80,333)
           
Operating profit 3,822,962 4,600,181 6,056,668 6,794,952 7,574,482
Finance costs (74,337) (32,426) (12,232) (7,664) (24,891)
Share of results of          
   — an asssociate (20,917) (23,894) (42,509)
   — a joint venture 43,554 58,407 34,449 46,337 27,114
Gain on deemed disposal of partial interest in an associate 37,192 13,092 31,897
Gain on deemed disposal of partial interest in a joint venture 16,168
Gain on disposal of a joint venture 24,273
Gain on disposal of a subsidiary 314,901
Loss on deemed disposal of a subsidiary (19,038)
           
Profit before taxes 3,792,179 4,626,162 6,391,023 6,847,096 7,582,261
Income tax expense (733,760) (892,810) (1,162,013) (1,158,972) (1,350,211)
           
Profit for the year 3,058,419 3,733,352 5,229,010 5,688,124 6,232,050
           
Profit for the year attributable to:          
   Owners of the company 3,080,802 3,714,106 5,159,655 5,605,185 6,091,390
   Non-controlling interests (22,383) 19,246 69,355 82,939 140,660
           
  3,058,419 3,733,352 5,229,010 5,688,124 6,232,050
           
  RMB cents
(Restated)
RMB cents
(Restated)
RMB cents
(Restated)
RMB cents RMB cents
Earnings per share          
   — basic 49.36 31.07 43.16 46.89 51.11
           
   — diluted N/A 31.07 43.16 46.89 51.11



  As at 31 December
  2018
RMB'000
(Restated)
2019
RMB'000
 
2020
RMB'000
 
2021
RMB'000
 
2022
RMB'000
 
Assets and liabilities          
Total assets 23,216,837 26,318,322 30,070,206 34,741,576 41,769,774
Total liabilities (7,687,237) (6,800,157) (6,969,133) (7,913,345) (10,127,899)
         
Net assets 15,529,600 19,518,165 23,101,073 26,828,231 31,641,875
         
Equity attributable to owners of the Company 15,052,260 18,461,723 22,332,288 25,986,672 30,197,534
Non-controlling interests 477,340 1,056,442 768,785 841,559 1,444,341
         
Total equity 15,529,600 19,518,165 23,101,073 26,828,231 31,641,875
Note: Other gains or losses and research and development expenses were reclassified from other income, administrative expense and other expenses in the consolidated financial statements so as to conform with the current year presentation.
© Copyright 2024 CSPC Pharmaceutical Group Limited. All Rights Reserved.